Neuroscience News and Research

RSS

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

Low-income patients with brain tumors are less likely to be referred to specialty hospitals

African-American, Hispanic, and economically disadvantaged patients with brain tumors are significantly less likely to be referred to high-volume hospitals that specialize in neurosurgery than other patients of similar age, the same gender, and with similar comorbidities, according to new research by Johns Hopkins doctors.

17 Mar 2010

Primary results of CABG sub-analysis presented at ACC meeting

AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA™/BRILIQUE™) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.

17 Mar 2010

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

It has long been known that alcohol exposure is toxic to the developing fetus and can result in lifelong brain, cognitive and behavioral problems. Now, a new report out of UCLA shows that the effects of prenatal methamphetamine exposure - or worse, a combination of methamphetamine and alcohol - may be even more damaging.

17 Mar 2010

Shaking hands with robotic arm could help stroke patients learn to use arms again

Shaking hands with a robotic arm could be a new way to help stroke patients learn to use their arms again. Researchers writing in BioMed Central's open access Journal of NeuroEngineering and Rehabilitation report a pilot trial of the 'Braccio di Ferro' (Iron arm) robot in 10 patients.

16 Mar 2010

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.

16 Mar 2010

Aging and Alzheimer's disease: Novel brain imaging technologies help create new insights

The emergence of multiple new brain imaging technologies and the combined application of these new approaches is helping to create new insights into aging and Alzheimer's disease. One of the hallmarks of Alzheimer's disease is the deposition of amyloid beta protein in clumps or "plaques" within the brain. These plaques can be measured in humans with PET scans that use a chemical marker or radiotracer called 11C-PIB.

16 Mar 2010

Differences in brain's reward system may underlie vulnerability to psychopathy: Study

Normal individuals who scored high on a measure of impulsive/antisocial traits display a hypersensitive brain reward system, according to a brain imaging study by researchers at Vanderbilt University. The findings provide the first evidence of differences in the brain's reward system that may underlie vulnerability to what's typically referred to as psychopathy.

16 Mar 2010

Human brain processes predictable sensory input more efficiently

The human brain processes predictable sensory input more efficiently. Alink and colleagues based this conclusion on the characteristics of responses in the primary visual cortex. It is known that the primary visual cortex is critical for vision and that responses in this brain area create a map of what we are currently looking at.

16 Mar 2010

A guide on ethics and neuroscience

As scientists continue to explore how the brain works, using ever more sophisticated technology, it seems likely that new findings will radically alter the traditional understanding of human nature.

16 Mar 2010

International symposium to feature latest findings on vector-borne diseases in humans and plants

Leading insect vector biologists from around the world will gather at the University of California, Riverside for two days this month to discuss their latest research on vector-borne diseases in humans and plants.

16 Mar 2010

Tel Aviv University researcher uses magic tricks to treat children with locomotor disabilities

It's often hard to motivate youngsters with physical disabilities. But a new approach from a Tel Aviv University researcher bridges the worlds of behavior and science to help kids with paralysis and motor dysfunction improve their physical skills and inner confidence -- using a trick up her sleeve called "magic."

16 Mar 2010

Surprise stimulus temporarily blinds subsequent events

Reading this story requires you to willfully pay attention to the sentences and to tune out nearby conversations, the radio and other distractions. But if a fire alarm sounded, your attention would be involuntarily snatched away from the story to the blaring sound.

15 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

Eisai Inc. today announces that it has entered into a licensing agreement with the Johns Hopkins University's Brain Science Institute related to Eisai's GCPII (glutamate carboxypeptidase II) technology.

12 Mar 2010

University of Tennessee CST effectively detects cognitive abnormalities associated with Alzheimer's disease

Early detection is key to more effective treatment for Alzheimer's disease and other forms of cognitive impairment, and new research shows that a test developed at the University of Tennessee is more than 95 percent effective in detecting cognitive abnormalities associated with these diseases.

12 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

BDNF could someday play significant role in prevention of high blood pressure: Study

Researchers at Oregon Health & Science University's School of Dentistry (www.ohsu.edu/sod) have discovered that nitric oxide is a powerful regulator of a molecule that plays a critical role in the development and function of the nervous system. The finding could someday play a significant role in the prevention and treatment of high blood pressure, which affects about one in three adults in the United States.

12 Mar 2010

Decision making: Replays in hippocampus part of complex process

Replaying recent events in the area of the brain called the hippocampus may have less to do with creating long-term memories, as scientists have suspected, than with an active decision-making process, suggests a new study by researchers at Carnegie Mellon University and the University of Minnesota Medical School.

12 Mar 2010

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

12 Mar 2010

Neuroscience News and Research

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

Low-income patients with brain tumors are less likely to be referred to specialty hospitals

Primary results of CABG sub-analysis presented at ACC meeting

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

Shaking hands with robotic arm could help stroke patients learn to use arms again

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Aging and Alzheimer's disease: Novel brain imaging technologies help create new insights

Differences in brain's reward system may underlie vulnerability to psychopathy: Study

Human brain processes predictable sensory input more efficiently

A guide on ethics and neuroscience

International symposium to feature latest findings on vector-borne diseases in humans and plants

Tel Aviv University researcher uses magic tricks to treat children with locomotor disabilities

Surprise stimulus temporarily blinds subsequent events

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

University of Tennessee CST effectively detects cognitive abnormalities associated with Alzheimer's disease

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

BDNF could someday play significant role in prevention of high blood pressure: Study

Decision making: Replays in hippocampus part of complex process

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Event guide: 2nd Neuroscience Innovation Partnering & Licensing Summit eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News